CLINICAL TRIALS PROFILE FOR DROXIA
✉ Email this page to a colleague
All Clinical Trials for DROXIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00354913 ↗ | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-05-01 | RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma. |
| NCT00354913 ↗ | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | Completed | Novartis Pharmaceuticals | Phase 2 | 2005-05-01 | RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma. |
| NCT00354913 ↗ | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | Completed | Duke University | Phase 2 | 2005-05-01 | RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma. |
| NCT01389024 ↗ | Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease | Active, not recruiting | Children's Hospital of Philadelphia | Phase 2 | 2011-10-01 | This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo for 36 months. Neither the study doctors nor the participants will know which treatment they are receiving. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DROXIA
Condition Name
Clinical Trial Locations for DROXIA
Trials by Country
Clinical Trial Progress for DROXIA
Clinical Trial Phase
Clinical Trial Sponsors for DROXIA
Sponsor Name
